Overview
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults because Janssen did not provide an evidence submission.
Last reviewed: 26 May 2021
Next review: We will review this decision if the company decides to make a submission.